Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3161028 | 0.81 | KDM4E (0.41) | KDM4EALDH1A1TSHRMAPK1NPSR1 | |
| SCHEMBL3842913 | 0.75 | KDM4E (0.36) | KDM4EALDH1A1TSHR | |
| SCHEMBL9940508 | 0.73 | HIF1A (0.41) | KDM4EALDH1A1 | |
| SCHEMBL10305113 | 0.72 | NR1H2 (0.40) | KDM4EALDH1A1OPRD1MAPK1NPSR1 | |
| SCHEMBL16287666 | 0.71 | KDM4E (0.40) | KDM4EALDH1A1TSHR | |
| SCHEMBL11354719 | 0.71 | KDM4E (0.42) | KDM4EMAP3K5ALDH1A1TSHRMAPK1 | |
| SCHEMBL8617913 | 0.69 | — | — | |
| SCHEMBL7666637 | 0.69 | — | — | |
| SCHEMBL14543239 | 0.68 | KDM4E (0.48) | KDM4EMAP3K5ALDH1A1TSHROPRD1 | |
| SCHEMBL16178136 | 0.67 | KDM4E (0.47) | KDM4EALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267697-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2010-10-21 | — | — | US | disclosed |
| EP-2099754-A1 | ION CHANNEL MODULATORS | Wyeth a Corporation of the State of Delaware (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008073929-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267697-A1 | ION CHANNEL MODULATORS | CACNA1E, CACNA1A, CACNA1S | KDM4E 1978/4885MAP3K5 3287/4885ALDH1A1 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.